Monte Rosa Therapeutics nets $95m Series C

Monte Rosa Therapeutics, a developer of precision medicines, has secured $95 million in Series C financing.

12 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles